Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Novel MR Antagonist Enters Japan PIII for Hypertension: Daiichi Sankyo
Daiichi Sankyo said on September 27 that it has launched a PIII trial in Japan for CS-3150 (esaxerenone (r-INN)), its non-steroidal, selective novel mineralocorticoid receptor (MR) antagonist, for the treatment of essential hypertension. The ESAX-HTN study will look into the…
To read the full story
Related Article
- Daiichi Sankyo Seeks Japan Approval for Hypertension Med Esaxerenone
February 28, 2018
BUSINESS
- Positive Price Revisions Seen at Several Firms in FY2026 Reform: Poll
March 6, 2026
- Sawai Pharmaceutical to Promote Toshiomi Nakate to President
March 6, 2026
- Asahi Kasei Pharma to Rebrand as Asahi Kasei Therapeutics in April
March 6, 2026
- Keytruda Maintains Top Spot for 29 Straight Months in February: Encise
March 6, 2026
- Takeda Files Japan NDA for Narcolepsy Drug Oveporexton
March 5, 2026
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…